Abcam commits to massive new Cambridge headquarters

Life science research tools supplier Abcam announced on Monday that it has committed to the lease of a new facility for its global headquarters at the Biomedical Campus in Cambridge, subject to the grant of full planning approval.

Abcam

1,226.00p

16:39 13/12/22

11.15%

123.00p

FTSE AIM 100

3,528.04

15:45 15/11/24

n/a

FTSE AIM 50

3,958.88

15:45 15/11/24

n/a

FTSE AIM All-Share

728.67

15:45 15/11/24

n/a

Pharmaceuticals & Biotechnology

19,259.77

15:45 15/11/24

-2.70%

-535.19

The AIM-traded firm said the purpose-built facility will place Abcam at the heart of an international centre for life science and clinical innovation, increasing collaboration opportunities with scientific opinion leaders and strengthening links with pharmaceutical discovery groups, institutions and clinicians.

It said the new site will allow it to combine its three current facilities in Cambridge into one new global headquarters, and will house the group's UK innovation and manufacturing capabilities, laboratories, logistics, sales, marketing and corporate functions and will be the company's European distribution hub.

With approximately 100,000 sq ft. of office and laboratory space, compared to the company’s current 57,000 sq ft., the facility will enable Abcam to better serve its consumers' needs, the board reported.

“The Cambridge Biomedical Campus is rapidly becoming an influential hub for global life science,” said Abcam CEO Alan Hirzel.

“We are looking forward to building upon our longstanding relationships with the scientific community and establishing new relationships with other organisations on the site.

“Bringing the Abcam team together will improve our efficiency and innovation process to the benefit of all of our stakeholders,” Hirzel added.